$DXCM

Brown Michael Jon sold $156K of DXCM

Brown Michael Jon (EVP Chief Legal Compliance Off) sold 1,700 shares of DEXCOM INC (DXCM) at $91.93 ($0.16M total) on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brown Michael Jon
Published Aug 17, 2026, 8:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DXCM
Neutral
high confidence
Mentioned
$DXCM
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for monitoring, but the 10b5-1 structure reduces the likelihood of a meaningful fundamental signal.

03

What to watch

The filing does not state tax, diversification, or other personal drivers; without follow-on buys/sells, it is hard to infer intent beyond routine compliance.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-17, sale dated 2026-08-14

Background

This is an SEC Form 4 insider transaction disclosure for DexCom, reported via EDGAR.

Company-level read

Ticker impact

$DXCMNeutralHigh confidence
Context

DexCom Form 4 shows EVP Chief Legal Compliance Off Brown sold 1,700 shares at $91.93 on 2026-08-14 under a 10b5-1 plan.

Expected impact

Likely negligible near-term impact; any effect would be sentiment-only and should fade as it is pre-arranged.

Evidence & confidence

The filing is a scheduled open-market sale under a pre-arranged Rule 10b5-1 plan, with no accompanying operational or guidance change disclosed.

Market effects

No sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is 10b5-1, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it for price direction.

Key entities

  • DexCom Inc

    Subject of the Form 4 insider sale disclosure.

  • Michael Jon Brown

    EVP, Chief Legal Compliance Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DXCMHighAI 8/10

DexCom stock hits 52-week high at 91.99 USD

DexCom Inc (DXCM) stock reached a 52-week high of $92.01, with a 36% year-to-date return. The company reported Q2 revenue of $1.308B, up 13% YoY, and raised its financial guidance. Analysts increased price targets, with Piper Sandler setting a $95 target. DexCom's inclusion in the FDA's TEMPO program and a perfect Piotroski Score of 9 indicate strong financial health.

$DXCMMed

Is Wall Street Bullish or Bearish on DexCom Stock?

DexCom (DXCM) designs continuous glucose monitoring systems. The stock lagged the S&P 500 and XLV over 52 weeks but gained 37.2% YTD. After Q2 2026 results on Jul. 30, adjusted EPS was $0.70 and revenue $1.31B, up 13% YoY, beating estimates. DexCom raised 2026 revenue guidance to $5.18B-$5.25B. Canaccord lifted its price target to $90; mean target $92.48.